| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/03/2023 | 149.67% | Wells Fargo | → $19 | Upgrades | Equal-Weight → Overweight |
| 10/13/2022 | 189.09% | UBS | → $22 | Initiates Coverage On | → Buy |
| 08/15/2022 | 162.81% | Jefferies | → $20 | Initiates Coverage On | → Buy |
| 05/12/2022 | 175.95% | Piper Sandler | $40 → $21 | Maintains | Overweight |
| 04/28/2022 | 149.67% | Credit Suisse | → $19 | Initiates Coverage On | → Neutral |
| 02/10/2022 | 149.67% | Wells Fargo | → $19 | Initiates Coverage On | → Equal-Weight |
| 10/14/2021 | 162.81% | SVB Leerink | → $20 | Initiates Coverage On | → Market Perform |
| 07/19/2021 | 294.22% | Guggenheim | → $30 | Initiates Coverage On | → Buy |
| 07/19/2021 | 425.62% | Piper Sandler | → $40 | Initiates Coverage On | → Overweight |
| 07/19/2021 | 399.34% | JP Morgan | → $38 | Initiates Coverage On | → Overweight |
What is the target price for Monte Rosa Therapeutics (GLUE)?
The latest price target for Monte Rosa Therapeutics (NASDAQ: GLUE) was reported by Wells Fargo on January 3, 2023. The analyst firm set a price target for $19.00 expecting GLUE to rise to within 12 months (a possible 149.67% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Monte Rosa Therapeutics (GLUE)?
The latest analyst rating for Monte Rosa Therapeutics (NASDAQ: GLUE) was provided by Wells Fargo, and Monte Rosa Therapeutics upgraded their overweight rating.
When is the next analyst rating going to be posted or updated for Monte Rosa Therapeutics (GLUE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Monte Rosa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Monte Rosa Therapeutics was filed on January 3, 2023 so you should expect the next rating to be made available sometime around January 3, 2024.
Is the Analyst Rating Monte Rosa Therapeutics (GLUE) correct?
While ratings are subjective and will change, the latest Monte Rosa Therapeutics (GLUE) rating was a upgraded with a price target of $0.00 to $19.00. The current price Monte Rosa Therapeutics (GLUE) is trading at is $7.61, which is within the analyst's predicted range.